Pulmatrix (PULM) FCF Margin (2014 - 2024)
Pulmatrix (PULM) posted FCF Margin of 59366.67% for Q4 2024, down 8457.78% sequentially from 693.72% in Q3 2024, and down 5931517.0% YoY from N/an in Q1 2024.
Pulmatrix (PULM) FCF Margin (2014 - 2024) Analysis & Trends
Pulmatrix has reported FCF Margin for 11 years, with the latest figure at 59366.67% in Q4 2024.
- Quarterly FCF Margin fell 5931517.0% year-over-year to 59366.67% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 142.38% (up 7374.0% YoY) and the FY2024 annual result came in at 142.38%, up 7374.0% from the prior year.
- FCF Margin eased to 59366.67% in Q4 2024 per PULM's latest filing, from 693.72% in the prior quarter.
- Over five years, FCF Margin peaked at 25.42% in Q1 2020 and troughed at 59366.67% in Q4 2024.
- A 5-year average of 3252.12% and a median of 280.15% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2024: FCF Margin surged 67659 bps in 2022, then sank 5931517 bps in 2024.
- Over 5 years, FCF Margin stood at 142.55% in 2020, then tumbled by 580 bps to 969.74% in 2021, then surged by 70 bps to 293.15% in 2022, then soared by 82 bps to 51.5% in 2023, then tumbled by 115178 bps to 59366.67% in 2024.
- According to Business Quant data, FCF Margin over the past three periods registered 59366.67%, 693.72%, and 265.21% for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 70.82% |
| 10 | Pulmatrix | 5.62 Mn | 5.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -59,366.67% |
| Sep 30, 2024 | -693.72% |
| Jun 30, 2024 | -265.21% |
| Mar 31, 2024 | -45.51% |
| Dec 31, 2023 | -51.50% |
| Sep 30, 2023 | -270.85% |
| Jun 30, 2023 | -241.43% |
| Mar 31, 2023 | -362.78% |
| Dec 31, 2022 | -293.15% |
| Sep 30, 2022 | -211.27% |
| Jun 30, 2022 | -347.78% |
| Mar 31, 2022 | -530.52% |
| Dec 31, 2021 | -969.74% |
| Sep 30, 2021 | -319.18% |
| Jun 30, 2021 | -289.44% |
| Mar 31, 2021 | -395.32% |
| Dec 31, 2020 | -142.55% |
| Sep 30, 2020 | -128.43% |
| Jun 30, 2020 | -142.86% |
| Mar 31, 2020 | 25.42% |